New AI Model Predicts Organ-Specific Aging and Identifies Anti-Aging Drug Targets
Researchers develop 2A model that tracks aging patterns across 16 organs, revealing lungs and kidneys age fastest while identifying promising drugs.
Summary
Scientists created the 2A model, an AI system that tracks aging across 16 different organs using gene expression data from mice. The model revealed that organs age at different rates, with lungs and kidneys being most vulnerable. It identified specific genes that change predictably with age and successfully predicted which drugs might slow aging, including metformin and two other compounds. The model outperformed existing aging assessment tools and could help develop personalized anti-aging treatments.
Detailed Summary
Aging affects different organs at varying rates, but most research has focused on comparing young versus old individuals rather than tracking the gradual aging process. This study addresses that gap by developing a comprehensive aging assessment model called 2A that monitors how 16 different organs age over time.
Researchers analyzed gene expression data from mouse organs spanning ages 1 to 27 months, identifying 'aging trend genes' that change predictably with age. They discovered that each organ has its own unique aging signature, with lungs and kidneys showing the greatest susceptibility to age-related decline. The model revealed that immune dysfunction and programmed cell death are key drivers of organ aging.
The 2A model demonstrated superior accuracy compared to existing aging clocks when tested on single-cell data and successfully predicted aging states in both mouse and human tissues. Importantly, it could predict how effectively certain treatments clear senescent cells from tissues. The researchers validated their findings using multiple independent datasets and confirmed that plasma cell accumulation and naive cell reduction occur linearly during aging.
Using the model's insights, the team screened for potential anti-aging drugs and identified three promising candidates: fostamatinib, ranolazine, and metformin. These drugs work through pathways involving longevity regulation and circadian rhythms. The model's ability to identify organ-specific aging patterns opens new possibilities for precision anti-aging therapies tailored to individual organ systems.
This research represents a significant advance in understanding how aging affects different parts of the body and provides a framework for developing targeted interventions to slow age-related decline in specific organs.
Key Findings
- Lungs and kidneys show highest susceptibility to aging among 16 organs studied
- Each organ has unique aging gene signatures and timelines
- Model identified fostamatinib, ranolazine, and metformin as anti-aging drug candidates
- Immune dysfunction and cell death are primary drivers of organ aging
- 2A model outperformed existing aging assessment tools in accuracy
Methodology
Researchers analyzed RNA sequencing data from 16 mouse organs across lifespans (1-27 months) using machine learning to identify aging trend genes. The 2A model was validated using multiple independent datasets including human tissue samples and single-cell sequencing data.
Study Limitations
Study primarily used mouse models, requiring validation in human populations. The identified drug candidates need clinical testing to confirm anti-aging effects. Long-term safety and efficacy of organ-specific interventions remain to be established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.